TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02191111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-focused facilitation
Description: An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
Study: NCT02614001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA
Description: Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: post-stroke rehabilitation program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post-stroke rehabilitation program
Study: NCT01708356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling on a residential route
Study: NCT03520998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6019
Description: GRF6019 for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6019
Description: GRF6019 for IV infusion
Study: NCT02621450

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: standart dialysis
Description: dialysate sodium consentration 140 mEq

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: low sodium dialysis
Description: dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
Study: NCT01473888

Intervention type: DRUG
Group type: OTHER
Intervention: T89(Dantonic)
Description: capsule, 225mg B.I.D.
Study: NCT05304754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells stimulated ex vivo with IL-15
Description: When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloreactive NK cells
Description: When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
Study: NCT03207295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
Study: NCT01988155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercise
Description: Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astym
Description: In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
Study: NCT02578069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVA Intracranial Sirolimus Eluting Stent System
Description: A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apollo Intracranial Stent System
Description: A 316L stainless steel balloon-expandable intracranial stent system
Study: NCT01062932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloserine
Description: Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo pill on Days 1, 4, 7, and 10
Study: NCT00653510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
Study: NCT00400465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal dressing
Description: Normal dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure dressing
Description: Pressure dressing
Study: NCT03228550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Efamol Active 50+
Description: 1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Efamol Active 50+
Description: 1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Static exercise cycle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Static exercise cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo multinutrient
Description: Placebo multinutrient supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo multinutrient
Description: Placebo multinutrient supplement
Study: NCT03755310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: First week: 10 mg tabs; Second week: 10-20 mg tabs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent dosage, route of administration and dose regimen
Study: NCT01919502

Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative urine pregnancy test
Study: NCT03905018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil 20 MG
Description: tadalafil 20 mg orally ,after a single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: tadalafil 20 mg orally ,after a single administration
Study: NCT00907335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retin-A Micro 0.04% facial acne treatment
Description: Retin-A Micro 0.04% facial acne treatment used once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Color-matched facial gel vehicle control used once daily
Study: NCT04232722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenicals
Description: As4 S4
Study: NCT00424710

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab intravitreal injection
Description: liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
Study: NCT02891499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: 1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: 1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediate force application
Description: Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediate force application
Description: Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
Study: NCT01459211

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide & Dexamethasone
Description: Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity
Study: NCT04444726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra Violet A Device.+ Topical medical treatment
Description: Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis device + Topical medical treatment
Description: Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Description: thin film of the cream is being applied to the affected areas for 2 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Description: thin film of the cream is being applied to the affected areas for 2 times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Description: thin film of the cream is being applied to the affected areas for 2 times per day.
Study: NCT01128634

Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719
Description: 13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.

Intervention type: DRUG
Group type: OTHER
Intervention: GW573719/GW573719
Description: 13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Study: NCT01532596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: 8-week standardized mindfulness meditation training program
Study: NCT01412502

Intervention type: OTHER
Intervention: IES-R and HDAS scores
Description: The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.

Intervention type: OTHER
Intervention: IES-R and HDAS scores
Description: The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.

Intervention type: OTHER
Intervention: IES-R and HDAS scores
Description: The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
Study: NCT04683484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,5 mg Al PO4
Study: NCT01670084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT01114698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ26489112
Description: JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
Study: NCT05182593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet moderate/high in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet moderate/high in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
Study: NCT00003475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02556177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scanning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scanning
Study: NCT03697252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo Capsules
Study: NCT01745939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Manipulation
Description: Manual therapy intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: Manual therapy intervention
Study: NCT02889952

Intervention type: DEVICE
Intervention: Near infrared camera (NIR)
Description: Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device).
Study: NCT01278225

Intervention type: BEHAVIORAL
Intervention: EEG biofeedback (BF) Group
Description: Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.

Intervention type: BEHAVIORAL
Intervention: Wait-List Control (WLC) Group
Description: Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.

Intervention type: BEHAVIORAL
Intervention: Follow UP Questionnaires
Description: After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.

Intervention type: BEHAVIORAL
Intervention: Follow UP Questionnaires
Description: After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
Study: NCT04123197

Intervention type: OTHER
Group type: OTHER
Intervention: Stress Challenge
Description: The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
Study: NCT04404413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity interval training (HIIT)
Description: 2x8 weeks of high-intensity interval training (HIIT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity interval training (HIIT) + intermittent fasting
Description: 2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
Study: NCT03435250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study: NCT02241616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir+Fuzheng Huayu+TCM Granule
Description: The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.